Abstract: A method for preventing cognitive decline, comprises the steps of identifying, in an individual, a first stage of cognitive decline corresponding to Subjective Cognitive Impairment and administering a predetermined treatment to the individual to inhibit a progression of the individual to a second predetermined stage of cognitive decline or to inhibit progression of cognitive decline within the first stage.

Abstract: A method for the identification of treatments and preventative agents for brain aging, subjective cognitive impairment (SCI), mild cognitive impairment (MCI), Alzheimer's disease (AD) and other degenerative dementias, the method including (a) the identification of the diagnosis and stage of the subject, (b) the identification of the duration of the stage of the condition and/or disorder, (c) the identification of prognostic markers based upon a formula incorporating the duration of the condition and/or stage, (d) the prospective separation of prognostic subgroups based upon outcome wherein the outcome is defined in these conditions as progression to a subsequent stage or stages, (e) the employment of a putative prognostic marker for an appropriate period of time, based upon the formula incorporating the duration of the condition and/or stage, (f) the application of in vivo, methodology specific techniques, in conjunction with stage specific prognostic subgroups, for the appropriate time period, for the identi

Abstract: Therapeutic methods for treatment of age associated memory impairment (AAMI), mild cognitive impairment (MCI), Alzheimer's disease (AD), cerebrovascular dementia (CVD), and related neurodegenerative conditions by administering an agent capable of inhibiting cell cycle progression, comprising administering one or more agents that are capable of inhibiting neuronal cell cycle progression at either an early cell cycle phase or generally, either alone or in combination with one or more agents capable of reducing mitogenic stimulation.

Abstract: A method is provided for the care and treatment of AD and related dementias by staging patients using the FAST, BCRS, and/or the GDS staging elements, translation of the staging elements into corresponding developmental ages (DAs), using the patient DA to determine the overall management and care needs of patients with AD and related retrogenic dementias, refining these needs based upon axioms refined by postulates and caveats.

Abstract: The present invention relates to the treatment of behavioral disorders, especially agitation, associated with a central nervous system (CNS) disorder, especially Alzheimer's disease (AD), cerebrovascular disease (VaD), or Down's Syndrome, in a mammal, comprising administering to said mammal an 1-aminocyclohexane, alone or in combination with a acetylcholinesterase inhibitor. In one embodiment, the 1-aminocyclohexane is memantine.

Abstract: A method is provided for the care and treatment of AD and related dementias by staging patients using the FAST, BCRS, and/or the GDS staging elements, translation of the staging elements into corresponding developmental ages (DAs), using the patient DA to determine the overall management and care needs of patients with AD and related retrogenic dementias, refining these needs based upon axioms refined by postulates and caveats.

Abstract: Therapeutic methods for treatment of age associated memory impairment (AAMI), mild cognitive impairment (MCI), Alzheimer's disease (AD), cerebrovascular dementia (CVD), and related neurodegenerative conditions by administering an agent capable of inhibiting cell cycle progression, comprising administering one or more agents that are capable of inhibiting neuronal cell cycle progression at either an early cell cycle phase or generally, either alone or in combination with one or more agents capable of reducing mitogenic stimulation.

Abstract: A method for differentiating cognitively normal elderly individuals from mildly demented patients with Alzheimer's disease by monitoring motor/psychomotor test results by the use of various computer monitored transducer apparatus attached to the individual while the individual undergoes testing. Head tracking ability, head steadiness, EMG-Arm extension tracking, and joint position matching are measured parameters used in the method.

Abstract: Neurologic measures, namely the hand grasp reflex (syn. palmar grasp reflex), the foot grasp reflex (syn. plantar grasp reflex), the tactile sucking reflex, and the extensor plantar reflex, and, additionally, when a specific magnitude of activity and cut-off score is applied, alone and especially in certain combinations, are used to diagnose the nature and cause of loss of voluntary urinary bladder and bowel control (syn. incontinence), for example, in Alzheimer disease.

Abstract: The clinical severity of Alzheimer's Disease in the elderly may be determined by measurement of contractures which correlate with the clinical severity of the disease. A goniometer may be used to determine the existence and degree of such contractures.

Abstract: Deep tendon reflexes, plantar responses, muscle tone and release signs were studied as 14 individual clinical variables and as 5 summary variables in 135 aged subjects, including 27 controls, 20 subjects with mild cognitive impairment, and 88 subjects with successive stages of probable Alzheimer's disease (AD). Changes in activity of elicited responses were rated on a seven-point scale. Results were analyzed both as prevalence and mean degree of change in activity. Mild cognitive impairment was associated with a significantly higher rating than controls on a variable combining all 14 individual variables. Subjects with early AD had both higher prevalence of increased activity and increased mean scores of deep tendon reflexes and muscle tone. They had a higher prevalence of increased activity on a variable combining three release signs. Patients with late stage AD had significantly increased prevalence and mean scores of muscle tone, grasping and sucking reflexes compared with controls and early AD patients.

Abstract: A method for the cognitive assessment of adult patients with severe dementia. The method proceeds by adapting cognitive assessment tests for infants to the special requirements of such patients.

Abstract: A process is disclosed for treating human memory impairment associated with aging, such as occurs in Alzheimer's disease, by administering a central nervous system cholinergic precursor such as lecithin or a choline salt in construction with a metabolic enhancer such as piracetam.